{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"95.0","value":"0"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"95.0","value":"0"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"45.1","value":"0"},{"groupId":"OG003","lowerLimit":"0.0","upperLimit":"25.9","value":"0"},{"groupId":"OG004","lowerLimit":"0.0","upperLimit":"16.2","value":"0"},{"groupId":"OG005","lowerLimit":"0.0","upperLimit":"20.6","value":"0"},{"groupId":"OG006","lowerLimit":"0.0","upperLimit":"45.1","value":"0"},{"groupId":"OG007","lowerLimit":"0.0","upperLimit":"52.7","value":"0"},{"groupId":"OG008","lowerLimit":"0.0","upperLimit":"31.2","value":"0"},{"groupId":"OG009","lowerLimit":"0.0","upperLimit":"9.2","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"8"},{"groupId":"OG009","value":"31"}],"units":"Participants"}],"description":"Objective response rate (ORR) was defined as the percentage of participants who achieved confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Confirmed responses were those that persisted on repeat imaging assessments at least 4 weeks after initial documentation of response. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \\<10 millimeters (mm). PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received TAK-186, Dose A as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose A is the lowest dose.","id":"OG000","title":"Dose Escalation Phase: TAK-186 - Dose A + Dexamethasone"},{"description":"Participants received TAK-186, Dose B as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose B is higher than Dose A.","id":"OG001","title":"Dose Escalation Phase: TAK-186 -Dose B + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose C is higher than Dose B.","id":"OG002","title":"Dose Escalation Phase: TAK-186 -Dose B → Dose C + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose D on Day 8 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B.","id":"OG003","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose E is higher than Dose C and B.","id":"OG004","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG005","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose E + Double Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose F on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose F is highest dose and is higher than Dose B and C.","id":"OG006","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose F + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion. Dose D is higher than Dose B and C.","id":"OG007","title":"Dose Escalation Phase: TAK-186 - Dose B → Dose C→ Dose D + Dexamethasone"},{"description":"Participants received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose D on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose D is higher than Dose B and C.","id":"OG008","title":"Dose Escalation Phase:TAK-186 - Dose B → Dose C→ Dose D + Double Dexamethasone"},{"description":"Participants with NSCLC received TAK-186, Dose B on Day 1 followed by Dose C on Day 8 and Dose E on Day 15 and thereafter as an IV infusion, QW until PD, completion of 7 cycles in the event of no radiologic evidence of tumor regression, withdrawal of consent, or death. Dexamethasone was administered pre-infusion and post-infusion. Dose E is higher than Dose C and B.","id":"OG009","title":"Cohort Expansion Phase: NSCLC"}],"paramType":"NUMBER","populationDescription":"Safety population included all participants who received at least 1 dose of TAK-186.","reportingStatus":"POSTED","timeFrame":"From start of study drug up to end of study (up to 22 months)","title":"Percentage of Participants With Objective Response (OR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}